Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

EPIC-HR, 2021
 
NCT04960202
RCTnirmatrelvir / ritonavir (Paxlovid)placeboCOVID 19 outpatientslow
1120/1126 conclusif
  • demonstrated 88 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
  • suggested 96 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias
  • suggested 90 % decrease in hospitalization or death with a high degree of certainty due to low risk of bias
  • suggested 88 % decrease in hospitalization or death with a high degree of certainty due to low risk of bias
  • statistically significant 76 % increase in related AE (TRAE) with a high degree of certainty due to low risk of bias
Based on laboratory studies only, Paxlovid is also expected to be active against Omicron and other variants.

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).